Initial assessment of a cancer genomic profile test for patients with metastatic breast cancer: a retrospective study

Ippei Fukada (ippei.fukada@jfcr.or.jp)
Genomic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Seiichi Mori
Division of Cancer Genomics, Japanese Foundation for Cancer Research, Cancer Institute

Naomi Hayashi
Genomic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Mari Hosonaga
Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Masumi Yamazaki
Genomic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Xiaofei Wang
Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Saori Kawai
Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Lina Inagaki
Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Yukinori Ozaki
Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Kokoro Kobayashi
Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Fumikata Hara
Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Takayuki Kobayashi
Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Arisa Ueki
Clinical Genetic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research

Tomo Osako
Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research

Akiko Tonooka
Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research

Kengo Takeuchi
Research Article

Keywords: cancer genomic profile (CGP), luminal-HER2, Genomics England, MHLW

Posted Date: October 1st, 2021

DOI: https://doi.org/10.21203/rs.3.rs-936695/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Comprehensive cancer genomic profile (CGP) tests are being implemented under Japanese universal health insurance system. However, the clinical usefulness of CGP test for breast cancer patients has not been evaluated. Of the 310 patients who underwent CGP testing at our institution between November 2019 and April 2021, 35 patients with metastatic breast cancer whose treatment strategy was discussed by our molecular tumor board within the study period were investigated after exclusion of 2 cases that could not be analyzed. The turn-around time, drug accessibility, and germline identification detection were evaluated. The subtype was luminal in 20 patients (57.1%), triple-negative in 12 patients (34.3%), and luminal-HER2 in 3 patients (8.6%). Actionable gene mutations were detected in 30 patients (85.7%), and 7 patients (20.0%) were recommended for clinical trial participation, with the drug administered to 2 patients (5.7%). Three patients (8.6%) died due to disease progression before the test results were disclosed. We report the results of an initial assessment of the utility of CGP testing for patients with metastatic breast cancer under Japanese universal health insurance system. Conducting CGP tests at a more appropriate time could provide patients with greater benefit from treatments based on their specific gene mutations.

Introduction

It is estimated that approximately one million people develop cancer each year, and nearly one in every two people develop cancer during their lifetime (1). Cancer genomic medicine, which enables more effective and efficient diagnosis, treatment, and prevention, is receiving increasing interest. In the United States, then-President Barack Obama announced the "Precision Medicine Initiative" in his State of the Union address in January 2015 (2), and in January 2016, the Vice President led the launch of the "Cancer Moonshot" project, which aimed to develop new diagnostic and treatment methods to overcome cancer (3). In the UK, Genomics England, established by the UK Department of Health in 2013, is implementing the "100,000 Genomes Project" to analyze the whole genome of patients with cancer and rare diseases. In December 2018, Genomics England announced the completion of the 100,000 Genomes Project analysis (4). In addition, in October of the same year, the UK Minister of Health announced the goal of conducting one million whole-genome analyses over the next 5 years.

In Japan, two types of "cancer genomic profile (CGP) tests" (OncoGuide NCC Oncopanel System and FoundationOne CDx Cancer Genome Profile) entered full-scale application under the universal health insurance system in June 2019 (5–8). In accordance with the Clinical Practice Guidance for Next-Generation Sequencing in Cancer Diagnosis and Treatment (edition 2.1), the gene panel tests covered by insurance include those for patients with solid tumors for whom no standard treatment is available or for whom standard treatment has been completed (including those who are expected to complete such treatment) (8–10). In addition, for the purpose of consolidating precision oncology treatment with quality control and assurance in designated hospitals, the Ministry of Health, Labour and Welfare (MHLW) originally designated 12 cancer genomic medicine core hospitals, 33 hub hospitals, and 180 cooperative hospitals in April 2021 (8, 11).
CGP tests use next-generation sequencing and other technologies to analyze a large number of cancer-related genes simultaneously, which is expected to assist in determining treatment strategies, thereby improving cancer treatment outcomes. In the SAFIR01 study, 423 patients with metastatic breast cancer underwent gene panel testing, which identified actionable mutations in 195 patients (46%). The mutations commonly identified included PIK3CA mutation (25%), CCND1 amplification (18%), and FGFR1 amplification (12%), followed by AKT1 mutation, EGFR amplification, and MDM2 amplification. A total of 55 of these patients (13%) were treated based on identified gene mutations (12).

The TOP-GEAR (Trial of Onco-Panel for Gene-profiling to Estimate both Adverse events and Response) project, a study using CGP testing, reported patient access to therapeutic agents after standard treatment in Japan. From May 2016 to May 2017, approximately half of the patients who participated in the project and were able to undergo genetic analysis were found to have abnormalities in actionable genes, and 25 patients (13.4%) received therapeutic drugs tailored to their individual gene mutations, of which only one involved breast cancer (13).

The CGP tests are being implemented in Japan under the universal health insurance program, but many issues remain to be resolved, such as the limited number of implementation targets after standard treatment, the complexity of the national insurance requirements, management of the molecular tumor board (expert panel), and drug accessibility. Therefore, the clinical usefulness of CGP testing for breast cancer patients has not been evaluated. The purpose of the present study was to evaluate these issues at our institute under Japanese universal health insurance system.

**Patients And Methods**

**Patients**

Of the 310 patients who underwent CGP testing at our institution between November 2019 and April 2021, those with metastatic breast cancer whose treatment plan was discussed by the molecular tumor board within the study period were retrospectively studied, except for patients whose analysis failed. In Japan, insurance coverage for CGP tests is restricted to patients with advanced solid tumors exhibiting disease progression during standard therapy or patients for whom there are no appropriate standard treatments, including patients with rare cancers and carcinomas of unknown primary origin.

The study was approved by the Institutional Review Board of our institution (2021-1195), and data were collected in compliance with the ethical requirements of our institution.

**Pathological assessment**

Immunohistochemical subtypes were determined based on the primary tumor. Tumor sections were stained with hematoxylin-eosin (HE) and immunohistochemically examined for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) expression. Immunohistochemical assessment of ER and PgR expression was performed using antibodies against
ER, clone 1D5 (Dako Japan Inc., Tokyo, Japan), and for PgR, clone PgR636 (Dako Japan Inc.). Positive reactions for ER and PgR were defined as nuclear staining in ≥10% of cancer cells, and negative reactions were defined as staining in <10% of cancer cells. Hormone receptor positivity was defined as positivity in ER and/or PgR staining. HER2 positivity was defined as HER2 protein 3+ or HER2 gene amplification, according to the ASCO/CAP guidelines (14).

After combining ER, PgR, and HER2 data, patients were classified into four subtypes, defined as follows: luminal subtype, ER+ and/or PgR+, HER2−; luminal HER2 subtype, ER+ and/or PgR+, HER2+; HER2 subtype, ER−, PgR−, HER2+; and triple-negative subtype, ER−, PgR−, HER2−.

**CGP test**

The FoundationOne CDx Cancer Genomic Profile was used in this study (5). The FoundationOne CDx Cancer Genomic Profile (Foundation Medicine) is a CGP platform that applies next-generation sequencing to in vitro diagnostics with a hybrid capture-based target enrichment approach and whole-genome shotgun library construction in order to identify gene substitutions, insertions and deletions (indels), copy number alterations, and select rearrangements. The FoundationOne CDx Cancer Genomic Profile detects alterations in a total of 324 genes, including all coding exons of 309 cancer-related genes (substitutions, insertions and deletions, copy number alterations) and select intronic regions of 36 commonly rearranged genes. In addition, the FoundationOne CDx Cancer Genomic Profile simultaneously profiles for tumor mutation burden (TMB) as well as microsatellite instability (MSI) status.

The rates of CGP testing success, turn-around time (TAT), drug accessibility, and secondary finding detection were evaluated.

The pathologist selected the representative block from the patient's stored formalin-fixed paraffin embedded (FFPE) specimens and estimated the tumor content in the HE specimen. In addition, 10 to 25 slices of 5µm were prepared to achieve a tumor volume of at least 25 mm$^2$ square, which is the volume required for analysis, and submitted for CGP test.

**Molecular tumor board (Expert Panel)**

The molecular tumor board of our institute discussed the reports from CGP tests (FoundationOne CDx) in conjunction with the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) and generated final reports for the patients. The molecular tumor board consists of physicians specializing in cancer pharmacotherapy; physicians with expertise in genetic medicine; genetic counselors; pathologists; physicians with expertise in molecular genetics and cancer genomic medicine; and those with expertise in bioinformatics. The evidence levels for therapeutic efficacy were categorized as A to F, following the JSMO/JSCO/JCA guideline (10). The actionable gene mutations were defined as following, predictive evidence level D and more (10) and high-tumor mutation burden (after approval of pembrolizumab by FDA).

**Results**
Patient characteristics

The CONSORT diagram of the study is shown in Figure 1. Characteristics of the 35 patients investigated in detail are listed in Table 1. All evaluated patients had invasive breast cancer. The median age of the patients was 56 years (range 32-81 years). Evaluation of histological type as established by needle biopsy or surgical specimen showed that more than half of the patients had invasive ductal carcinoma (54.3%). There were 7 specific types, including 4 cases of invasive lobular carcinoma (11.4%) and one case (2.9%) each of spindle cell carcinoma, mucinous carcinoma, and metaplastic carcinoma. The subtype was luminal in 20 patients (57.1%), triple-negative in 12 patients (34.3%), and luminal-HER2 in 3 patients (8.6%).
Table 1
Patient characteristics.

|                         | n=35 |   |
|-------------------------|------|---|
|                         | No.  | % |
| **Age (y)**             |      |   |
| Median                  | 56   |   |
| Range                   | 32 - 81 |   |
| 50>                     | 10   | 28.6 |
| 50 and more             | 25   | 71.4 |
| **Histological type**   |      |   |
| invasive ductal carcinoma | 26 | 74.3 |
| invasive lobular carcinoma | 4  | 11.4 |
| metaplastic carcinoma   | 2    | 5.7 |
| mucinous carcinoma      | 1    | 2.9 |
| apocrine carcinoma      | 1    | 2.9 |
| non-invasive ductal carcinoma | 1 | 2.9 |
| **Subtype**             |      |   |
| Luminal                 | 20   | 57.1 |
| Luminal-HER2            | 3    | 8.6 |
| Triple Negative         | 12   | 34.3 |
| **The number of pretreatment regimens** | |   |
| 1                       | 5    | 14.3 |
| 2                       | 4    | 11.4 |
| 3                       | 1    | 2.9 |
| 4                       | 7    | 20.0 |
| 5                       | 4    | 11.4 |
| 6                       | 3    | 8.6 |
| 7                       | 3    | 8.6 |
| 8                       | 2    | 5.7 |
The median number of pretreatment regimens, including regimens currently being treated, was 5 (range 1-16). In 5 cases, CGP testing was performed during the initial treatment of metastatic breast cancer, and 4 patients (11.4%) had ≥10 pretreatment regimens.

The specimens submitted for CGP testing included 23 primary breast sites (65.7%) and 12 biopsies from metastatic sites (34.3%). The biopsy specimens included one case of pleural fluid cell block.

### Type and frequency of identified genetic variants

The gene mutations and amplifications detected in this study are shown in Figure 2. As reported previously, TP53 and PIK3CA mutations were found in more than 40% of the cases. BRCA1/2 and RAD21C mutations were also found in approximately 30% of cases in this study.

Thirty cases (87.5%) involved actionable gene mutations, as shown in Figure 3. These included 21 cases (60.0%) of gene mutations, 11 cases (31.4%) of gene amplification, and 2 cases (5.7%) involving gene mutations (TMB) of ≥10 Mb; however, no cases involved gene fusion.

### Turn-around time

|               | n=35 |
|---------------|------|
| 9             | 2    |
| 10 and more   | 4    |

The specimens submitted for gene panel testing

| Site                      | Count |
|---------------------------|-------|
| primary breast sites      | 23    |
| biopsies from metastatic sites | 12    |
| metastatic sites          |       |
| axillary lymph nodes      | 2     |
| chest wall                | 2     |
| lung                      | 2     |
| skin                      | 1     |
| liver                     | 1     |
| pleural fluid cell block  | 1     |
| ovary                     | 1     |
| uterus                    | 1     |
| bone                      | 1     |
The median turn-around time from obtaining consent to the molecular tumor board was 44 days (range 29-93 days), and from obtaining consent to explaining the CGP test results was 56 days (range 42-105 days).

**Drug accessibility rate**

Among the 35 patients investigated in detail, the molecular tumor board recommended treatment according to the gene mutation for 7 patients (20%), but only 2 patients (5.7%) participated in clinical trials, as 5 patients were unable to undergo treatment for their mutations due to disease progression (Fig. 4). The 7 cases in which the molecular tumor board recommended treatment according to the gene mutation are shown in Table 2.

Table 2

| Case | Age | Subtype       | No. of previous treatments | Gene       | Candidate for therapy | Status of treatment                                           |
|------|-----|---------------|-----------------------------|------------|-----------------------|--------------------------------------------------------------|
| 1    | 58  | Luminal       | 11                          | FGFR1(amp) | TAS120                | participation in clinical trial                              |
| 2    | 68  | Luminal       | 9                           | FGFR1(amp) | TAS120                |                                                              |
| 3    | 39  | Triple negative | 1                          | RAD51C     | Olaparib              | Unable to participate in the recommended clinical trials due to disease progression |
| 4    | 50  | Luminal       | 5                           | FGF3/4/19 (amp) | TAS120          |                                                              |
| 5    | 45  | Triple negative | 2                          | TP53       | AMG650                |                                                              |
| 6    | 37  | Triple negative | 2                          | TP53       | AMG650                |                                                              |
|      |     |               |                              | FGFR1(amp) | TAS120                |                                                              |
| 7    | 62  | Luminal-HER2  | 10                          | FGFR2(amp) | Erdafitinib          | pre-treatment ongoing                                        |
|      |     |               |                              |            | TAS120          |                                                              |
|      |     |               |                              |            | TMB-high           | Nivolumab                                                    |
|      |     |               |                              |            |                      | Pembrolizumab                                                |

With regard to the status of CGP test result disclosure, 3 patients (8.6%) died due to disease progression before the test results were disclosed; thus, the results of the CGP tests could not be explained.

**Germline findings**

There were 9 cases in which germline pathological variants were suspected, among which 6 cases had known pathologic variants of *BRCA1/2* before the CGP test (Table 3). In the CGP test, *RAD51C, BRCA1,*
and PALB2 were identified as newly suspected germline variants in one case each. In a patient with triple-negative breast cancer suspected of having germline variants in RAD51C, confirmatory testing by specific site analysis revealed pathological variants in RAD51C. Patients with suspected germline variants in BRCA1 were confirmed negative by BRCA analysis.

Table 3
Cases involving suspected germline pathological variants.

| Case | Age | Subtype          | Gene     | Genetic counseling | Confirmatory test | Note                                         |
|------|-----|------------------|----------|--------------------|-------------------|------------------------------------------------|
| 1    | 39  | Triple negative  | RAD51C   | yes                | yes               | Specific site analysis revealed pathogenic variation |
| 2    | 37  | Triple negative  | BRCA1    | done               | known             |                                                |
| 3    | 57  | Luminal          | BRCA2    | done               | known             |                                                |
| 4    | 32  | Luminal          | BRCA2    | done               | known             |                                                |
| 5    | 39  | Luminal          | BRCA1    | done               | known             |                                                |
| 6    | 65  | Triple negative  | BRCA1    | yes                | yes               | Negative by BRCA analysis                      |
| 7    | 38  | Luminal          | BRCA1    | done               | known             |                                                |
| 8    | 42  | Luminal-HER2     | BRCA2    | done               | known             |                                                |
| 9    | 52  | Luminal          | PALB2    | none               | none              | Confirmatory tests could not be performed due to worsening of the patient's condition. |

Discussion

We report here for the first time the initial assessment of the utility of CGP testing for patients with metastatic breast cancer under Japanese universal health insurance system. In the first 18 months after implementation of reimbursement for CGP tests, 310 CGP tests were conducted in our institute during the study period. Thirty-seven patients with metastatic breast cancer were tested, followed by pancreatic cancer and colorectal cancer. Actionable gene mutations were detected in 30 patients (85.7%), and participation in a clinical trial was recommended to 7 patients (20.0%). The drug was administered to only 2 patients (5.7%), as 3 patients (8.6%) had newly suspected germline pathological variants, and the results were subject to disclosure.

As for the current status of CGP testing under universal health insurance in Japan, 805 patients underwent CGP testing between June and October 2019, and it was reported that 10.9% of these patients were then treated based on their gene mutations (15). Furthermore, according to a report from 11 core hospitals for cancer genomic medicine, among the 747 cases in which CGP tests were conducted (from
June 2019 to January 2020), 28 patients (3.7%) received genome-matched treatment (16). However, of these 28 patients treated according to their gene mutations, only 2 patients had breast cancer, and both were treated with an mTOR inhibitor for a $PIK3CA$ mutation in that study (16). As such, under national health insurance in Japan, only approximately 10% of the patients who underwent CGP testing received a therapeutic drug targeted to their gene mutations.

This study identified several important issues regarding CGP testing under Japanese universal insurance system. The first issue is the low rate of drug accessibility due to disease progression after CGP testing. The second issue is that approximately 8% of patients died due to disease progression before the test results were disclosed; thus, the results of the CGP tests could not be explained.

Possible causes of these issues include the indication and official pricing system of reimbursement of CGP testing covered by Japanese universal health insurance system. The indication for CGP testing covered by insurance in Japan is restricted to patients with advanced solid tumors exhibiting disease progression during standard therapy (including those expected to be completed) or patients for whom there are no appropriate standard treatments, including those with rare cancers and carcinoma of unknown primary origin (8–10). Furthermore, reimbursement for the cost of a CGP test is 560,000 yen, paid in two steps. The first reimbursement is 80,000 yen after applying for the informed consent for CGP testing and preparation of tumor samples. The second reimbursement of 480,000 yen is paid when the patient receives an explanation of the CGP test results after assessment by the molecular tumor board.

In our study, new treatment options, such as those available in clinical trials, were recommended to 7 patients (20.0%) by the molecular tumor board. However, 5 (14.3%) of these patients were unable to undergo genome-matched treatment due to disease progression after the CGP test. Although the definition of the standard treatment for metastatic breast cancer prior to CGP testing remains controversial, the treatments strongly recommended in the guidelines of the Japanese Breast Cancer Society are considered candidates in Japan (17). However, the patient may be eligible for CGP testing without all standard therapies, depending on the efficacy and safety of previous therapies, the patient’s general condition, and patient preference in consideration of the 6- to 8-week turnaround time from submission of tumor tissue to return of analysis results. Therefore, our results suggest that CGP testing conducted at the appropriate time and based on the efficacy of previous therapy, the patient’s general condition, and patient preference might improve the drug accessibility rate.

As mentioned above, CGP testing is currently restricted to patients who finished standard therapies in order to avoid unnecessary investigations and reduce the burden for the molecular tumor board. However, patients who finished standard therapies for metastatic or recurrent cancer tend to have poor prognosis due to disease progression. Therefore, it is important to perform the CGP test at the diagnosis of metastatic breast cancer. Also, changes to the insurance system should be considered, in addition to increasing the number of clinical trials and promoting efforts to standardize quality while reducing the burden on the molecular tumor board.
In summary, it has been almost 2 years since CGP testing covered by the universal health insurance system was first introduced in Japan, and implementation of cancer genomic medicine is progressing. We reported here the initial assessment of CGP testing for patients with metastatic breast cancer and revealed that the percentage of patients who could reach clinical trials is low. In our sample group, a number of patients died before the test results were disclosed, although more than 80% of the patients had actionable mutations. In order to make CGP testing clinically valuable for patients with metastatic breast cancer, it will be necessary to solve problems associated with the current program of insurance coverage for CGP testing in Japan.

**Conclusion**

We reported here the initial assessment of the utility of CGP testing for patients with metastatic breast cancer. In our institute, 5.7% of patients underwent genome-matched treatment, and 8.5% were found to have newly suspected germline variations. Conducting CGP tests at a more appropriate time could provide patients with greater benefit from treatments based on their specific gene mutations.

**Declarations**

**Ethics approval and consent to participate**

This retrospective study was approved by the Institutional Review Board of the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (2021-1195). Comprehensive written informed consent for the use of specimen materials was obtained from all patients participating as subjects in this study. In addition, we also used the official website of Cancer Institute Hospital as an opt-out method because of requirement from Japanese law in a non-invasive observational trial such as the present study. And all procedures performed in studies involving human participants were in accordance with the Declaration of 1964 Helsinki and the Ethical Guidelines for Medical and Health Research involving Human Subjects by Ministry of Health, Labour and Welfare (MHLW), the Ministry of Education, Culture, Sports, Science and Technology (MEXT), and the Ministry of Economy, Trade and Industry (METI) of Japan.

**Availability of data and materials**

The datasets collected during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Acknowledgments**

The authors would like to thank the patients who participated in this study and their families. The authors would also like to thank Teruaki Hitaka from Research Support and Kyoko Igarashi from the Expert Panel administrative office for their contributions to the management of the molecular tumor board.
Authors’ contributions

All authors contributed to the study conception and design. Material preparation, data collection, and data analysis were performed by I.F., N.H. and S.T. The first draft of the manuscript was written by I.F., and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Additional Information

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. CANCER STATISTICS IN JAPAN 2018. https://ganjo ho.jp/data/reg_stat/statistics/brochure/2018/cancer_statistics_2018_fig_E.pdf.
2. Collins, F. S. et al. A new initiative on precision medicine. N Engl J Med, 372 (9), 793–795 (2015).
3. Biden Progress Made with Cancer Moonshot. Cancer Discov, 7 (6), 542 (2017).
4. https://www.genomicsengland.co.uk/
5. The OncoGuide™ NCC oncopanel system receives insurance coverage for use in cancer genome profiling. https://www.sysme x.co.jp/en/news/2019/190531.html.
6. Chugai Launches Genomic Mutation Analysis Program, FoundationOne CDx Cancer Genomic Profile. https://www.chuga i-pharm.co.jp/english/news/detail/20190603150001_625.html.
7. Mukai, Y. et al. Establishment and implementation of Cancer Genomic Medicine in Japan. Cancer Sci, 112 (3), 970–977 (2021).
8. Ebi, H. et al. Precision Oncology and the Universal Health Coverage System in Japan. JCO Precis Oncol. 2019 Dec 11;3:PO.19.00291. doi: 10.1200/PO.19.00291.
9. https://nt/1240000/000514782.pdf.
10. Naito, Y. et al. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int J Clin Oncol, 26 (2), 233–283 (2021).
11. https://www.mhlw.go.jp/content/000597778.pdf
12. André, F. et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol, 15 (3), 267–274 (2014).
13. Sunami, K. et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci, 110 (4), 1480–1490 (2019).
14. Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *Arch Pathol Lab Med*, **138** (2), 241–256 (2014).

15. https://

16. Sunami, K. et al. The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan. *Int J Clin Oncol*, **26** (3), 443–449 (2021).

17. https://jbcs.xsrv.jp/guidline/2018/index/yakubutu/y2-fq-21/

**Figures**

![Study Consort Diagram](image-url)

Figure 1

Study Consort Diagram.
Figure 2

Type and frequency of identified genetic variants. The gene mutations and amplifications detected in this study are shown.
**Figure 3**

Actionable gene mutations identified in each case. Patients with actionable gene mutations are listed (n=30).
Drug accessibility rate Drug accessibility status is shown. Of the 30 patients in whom actionable gene mutations were detected, only 2 patients (5.7%) received genome-matched treatment.

Figure 4